Assessing Allergies in Minutes

Our technology is driven by one obvious observation – there is no excuse for poor quality healthcare due to lack of proper allergy evaluation. So, we created the solution.

The rising allergy epidemic

There is a significant, growing problem with allergies and the current solutions are not nearly enough to cater to the people who live with them. From proper identification to treatment plans, allergies cost the healthcare industry billions of dollars every year and misdiagnosis puts lives at risk.

150m +

People affected


Leading cause of chronic disease


In healthcare costs

Current solutions are insufficient

  1. No testing/experiential
    • No actual data
    • Patients spend the rest of their lives avoiding
  1. In office skin prick test
    • Multiple appointments
    • 2-hour appointment
    • Long wait for specialist
    • Insufficient capacity
Blood test
  1. IgE blood assay
    • Sent to special lab
    • Wait days for results
    • Less accurate

Changing the way allergy testing works

Our solution helps providers feel confident when crafting treatment plans. EpiSLS eliminates the multiple appointments, the long wait for results, the misdiagnosis, and the need for a specialist. EpiSLS provides the data to help healthcare professionals devise the best and most effective antibiotic therapy to customize each patient’s treatment plan.

epiSLS device

What makes epiSLS different?

  1. Designed by doctors and allergists: we utilized our 15+ years of experience along with other professionals to create a solution that works for the healthcare industry.
  1. AI-powered data analysis provides automated, accurate insights through complex data analysis that identifies allergens, compares cohorts, and provide immediate results.
  1. We built this device with cutting edge technology that utilizies innovative application and sensing technologies.
  1. It’s a less invasive process, only requiring a few drops of blood needed to uncover hypersensitivity.
  1. No specialists needed; any healthcare professional can administer the test and read the results.
  1. It’s a quick assessment performed at the point of care and completed within 30 minutes.
  1. It’s easy to manage because there is no need for multiple appointments or tests.

How our technology helps you know what, faster

EpiSLS is a medical device which offers the first option for point of care allergy testing in every care setting. Our system was designed to be accessible, affordable, and safe for any patient who is eligible to receive traditional in-office testing.

EpiSLS comprises two interlocking components: a reusable technology unit containing the sensing hardware and a replaceable, single use applicator unit acting as a reservoir and delivery tool for panels of allergens.

The epiSLS system utilizes an optical sensor that detects hypersensitivity reactions based on low energy light allowing it to bring this specialized care to patients no matter where they are or when they need it. This new method of measuring and characterizing immune cell activity directly in the skin allows the device to determine risk of systemic allergic reaction faster and more accurately than traditional methods.

epiSLS Technology

EpiSLS reconciles millions of datapoints to create a detailed reconstruction and quantifiable measure of what is happening inside a patient’s body. Here we see a visualized representation of two patient’s skin each showing the development of wheals meaning the patient is allergic.

Versatile applications across all type 1 allergies









Dust mites

Value creation for all stakeholders



Ability to screen allergies
Efficient treatment



Can use effective, less costly drugs
Reduced readmissions, costs, and complications



Access to allergy testing
Better healthcare outcomes

We are innovators looking for initiators.

We consider ourselves to be excellent at what we do, and we want to partner with others who are dedicated to also changing the face of healthcare. So, if you consider yourself to be that institutor, whether that’s an investor or a healthcare professional dedicated to improving patient care, then we should talk. We are just a conversation away from a great partnership.